New Full-Service Projects Drive 114% Increase in Bookings Over FY2012
Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today the company has closed its strongest year to date, with a record number of new clinical development projects and regulatory and strategic development engagements; driving 114% growth in bookings compared to the previous year.
Much of the company’s success in 2013 can be attributed to new client acquisition within both its Clinical and Regulatory divisions, as well as strong demand for additional projects within its existing base of clients.
2013 by the numbers:
“The continued growth in both new client acquisition and follow-on projects from existing clients demonstrates the level of trust and partnership we build with our clients,” said Jeff Williams, Clinipace Worldwide Founder and CEO. “We work hard to forge a real partnership with our clients and to provide efficiency and visibility into study and program management through our dCRO model.”
Clinipace also experienced solid growth in several therapeutic areas over the past year including oncology/hematology, infectious disease, gastroenterology, cardiovascular, nephrology, immunology, pediatrics, and women’s health. The company’s depth and breadth of expertise managing oncology clinical trials remains one of its strongest core competencies.
Clinipace hired 50 net new team members in 2013, and expects to expand by an additional 25% in 2014 to support continued growth. Areas of aggressive hiring included clinical monitoring, site management services, clinical project management, clinical data management, and financial operations.
Clinipace Worldwide was recognized this past year both regionally and nationally for its tremendous growth with several prestigious business awards. The company started off the year on a high note, ranking #36 in FORBES’ list of America’s 100 Most Promising Companies. In May, the Triangle Business Journal and accounting giant BDO honored Clinipace with one of its inaugural Life Sciences Awards. The company also was named to Inc. Magazine’s Inc. 500, upon generating a three-year growth rate of 918.55% from 2010 to 2012. This is the fourth consecutive year that Clinipace Worldwide has been recognized—an honor bestowed to few other companies in the nation. Clinipace was recognized for the fourth year in a row as one of the 50 fastest growing private companies in the Triangle at the Triangle Business Journal’s Fast 50 Awards. Clinipace also received the distinction of being chosen as an Inc. Magazine Hire Power Awards winner. Clinipace ranked 67th overall, placing it among the top 100 private business job creators in the country, 2nd in private business job creators within North Carolina, and 7th within the health industry.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
2 Commerce Drive
Cranbury, NJ 08512